T Hauge1, P W Hauge2, T Warloe3, A Drolsum4, C Johansen4, E Viktil4, L Aabakken5, T Buanes6, Z Konopski7. 1. Dept. of Gastroenterology, Oslo University Hospital, Norway; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway. Electronic address: truls.hauge@medisin.uio.no. 2. Dept. of Oncology, Oslo University Hospital, Norway. 3. Dept. of Gastroenterology, Oslo University Hospital, Norway; Division of Cancer, Surgery and Transplantation, Oslo University Hospital, Norway. 4. Dept. of Radiology and Nuclear Medicine, Oslo University Hospital, Norway. 5. Section of Gastroenterology, Oslo University Hospital, Norway; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway. 6. Division of Cancer, Surgery and Transplantation, Oslo University Hospital, Norway; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway. 7. Dept. of Gastroenterology, Oslo University Hospital, Norway.
Abstract
BACKGROUND:Photodynamic therapy (PDT) in combination with stent have shown promising results in the treatment of biliary tract cancer (BTC) in patients not suitable for surgery. Chemotherapy has been shown to improve survival in patients with local advanced and metastatic BTC. MATERIAL AND METHODS: In the current randomized trial the combination of chemotherapy and stent with and without temoporfin (Foscan) photodynamic therapy (PDT), with a primary endpoint on feasibility and safety, has been performed. Ten patients in each group. RESULTS: No serious, acute procedure-related complication related to PDT or the treatment combination was seen. The number of patients with cholangitis was equal in both groups. In the PDT group--arm A--two patients had cutaneous erythema after sun exposition, one of them with a localized blister. No neutropenic infection was seen. Quality of Life (QoL) was similar in both treatment groups. Progression free survival was numerically longer in the PDT group. CONCLUSION: The treatment combination was feasible. There was no serious complication related to PDT or the treatment combination. Number of cholangitis was equal in both groups, two abscesses were observed in the PDT group. Progression free survival was numerically longer in the PDT group.
RCT Entities:
BACKGROUND: Photodynamic therapy (PDT) in combination with stent have shown promising results in the treatment of biliary tract cancer (BTC) in patients not suitable for surgery. Chemotherapy has been shown to improve survival in patients with local advanced and metastatic BTC. MATERIAL AND METHODS: In the current randomized trial the combination of chemotherapy and stent with and without temoporfin (Foscan) photodynamic therapy (PDT), with a primary endpoint on feasibility and safety, has been performed. Ten patients in each group. RESULTS: No serious, acute procedure-related complication related to PDT or the treatment combination was seen. The number of patients with cholangitis was equal in both groups. In the PDT group--arm A--two patients had cutaneous erythema after sun exposition, one of them with a localized blister. No neutropenic infection was seen. Quality of Life (QoL) was similar in both treatment groups. Progression free survival was numerically longer in the PDT group. CONCLUSION: The treatment combination was feasible. There was no serious complication related to PDT or the treatment combination. Number of cholangitis was equal in both groups, two abscesses were observed in the PDT group. Progression free survival was numerically longer in the PDT group.
Authors: Jörg Trojan; Albrecht Hoffmeister; Bruno Neu; Stefan Kasper; Alexander Dechêne; Christian Jürgensen; Jörg Schirra; Ralf Jakobs; Dan Palmer; Pål K Selbo; Hans Olivecrona; Lena Finnesand; Anders Høgset; Per Walday; Richard Sturgess Journal: Oncologist Date: 2022-06-08 Impact factor: 5.837